EGFR and neoplasm: Like EGFR mutations, KRAS mutations were significantly more common in ADC than in SCC or other tumor types (36.9 %, 2.5 %, and 24.6 % respectively, p < 0.001) and there was a trend towards more mutations in female compared to male patients (36.4 % vs. 30.6 %, p = 0.090), but this did not reach statistical significance (Table 1).